Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Monitoring CV status in fingolimod patients crucial, says Novartis

    • 12 Accesses

    This is a preview of subscription content, log in to check access.

    REFERENCE

    1. 1.

      MHRA.Direct Healthcare Professional Communication on strengthening the cardiovascular monitoring during treatment initiation with Gilenya (fingolimod) in patients with Relapsing Remitting Multiple Sclerosis. Internet Document: [2 pages], 23 Jan 2012. Available from: URL: http://www.mhra.gov.uk

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Monitoring CV status in fingolimod patients crucial, says Novartis. React. Wkly. 1388, 2 (2012). https://doi.org/10.2165/00128415-201213880-00002

    Download citation

    Keywords

    • Public Health
    • Clinical Trial
    • Multiple Sclerosis
    • Healthcare Professional
    • Fingolimod